Evaluating Peginterferon for treating Essential Thrombocythemia and Polycythemia Vera

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study is a single-arm, single-center clinical trial that aims to recruit 40 participants diagnosed with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Participants will receive a weekly subcutaneous injection of Peginterferon α-2b at a dosage of 180 mcg, and the study will assess both the efficacy and safety of this treatment. The trial follows the 2016 WHO diagnostic criteria for ET and PV to ensure appropriate patient selection. Follow-up evaluations will be conducted to monitor treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Meet the 2016 WHO diagnostic criteria for ET (Essential Thrombocythemia) and PV (Polycythemia Vera)

   * ET (Essential Thrombocythemia) major criteria:

     1. Platelet count \> 450 \* 10\^9/L; (2) Bone marrow biopsy shows marked megakaryocytic proliferation with increased mature megakaryocyte volume and increased nuclear lobulation. There is no significant granulocytic proliferation, left shift, or erythroid proliferation, with grade 1 fibrosis observed in a few cases; (3) Does not meet the WHO diagnostic criteria for BCR-ABL1+ CML, PV, PMF, MDS, or other myeloproliferative neoplasms; (4) JAK2, CALR, or MPL mutation positive.

        Secondary criteria: (1) Presence of a clonal marker or absence of evidence for reactive thrombocytosis.

        The diagnosis of ET requires the fulfillment of all four main criteria, or the first three main criteria plus one secondary criterion.
   * PV (Polycythemia Vera) main criteria: (1) Hemoglobin \> 16.5 g/dL in males, \> 16 g/dL in females, or Hematocrit \> 49% in males, \> 48% in females, or an increase in red cell volume of 25% or more above the normal value; (2) Bone marrow biopsy shows increased cellularity inappropriate for age, with marked erythroid, granulocytic, and megakaryocytic proliferation, and the presence of mature megakaryocytes of varying sizes and morphologies; (3) JAK2 V617F mutation positive or JAK2 exon 12 mutation positive.

   Secondary criteria: Serum Epo (Erythropoietin) level below the lower limit of the normal range.

   The diagnosis of PV requires the fulfillment of three major criteria, or the first two main criteria plus one secondary criterion.
2. For ET patients, the criteria for cytoreductive therapy must be met, as follows:

(1) For patients without a history of thrombosis: Age ≥ 60 years, regardless of the presence of cardiovascular risk (CVR) or JAK2V617 mutation; Any age with a platelet count \> 1500 × 109/L. (2) For patients with a history of arterial thrombosis: Any age, regardless of the presence of CVR and JAK2V617 mutation; (3) For patients with a history of venous thrombosis: Any age, regardless of the presence of CVR and JAK2V617 mutation; 3.ECOG score ≤ 2. 4.Cardiac ejection fraction (EF) ≥ 60%. 5.The participant voluntarily signs the informed consent form.

Exclusion Criteria:

* Previous treatment with Peginterferon α-2b.
* ET patients who do not meet the criteria for cytoreductive therapy as per the 2016 Chinese Expert Consensus on Primary Thrombocythemia.
* Allergy to the active ingredient, α-interferon, or any excipients of this product.
* History of psychiatric illness, or allergy to interferon.
* Plasma total bilirubin greater than twice the normal value.
* Severe cardiac disease, liver insufficiency, chronic kidney disease, and neurological disorders (such as depression or mania).
* History of other malignant tumors within the past three years.
* Autoimmune chronic hepatitis.
* Any condition deemed unsuitable for inclusion by the investigator.

Where it's running

• Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: ZhenYa Hong, Ph.D — Tongji Medical College, Huazhong University of Science and Technology
• Study coordinator: ZhenYa Hong, Ph.D
• Email: hongzhenya@126.com
• Phone: 13476158466

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing ASTX727 with and without Iadademstat for advanced blood cancers

  This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 31 other locations · NCT06661915

• Evaluating GLB-001 for patients with myeloid malignancies

  This study is testing a new oral treatment called GLB-001 to see if it is safe and effective for people with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 14 sites Phase 1 Hangzhou GluBio Pharmaceutical Co., Ltd. · Hefei, Anhui and 13 other locations · NCT06378437

• Characterizing Monocytes in Blood Disorders

  This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.

  Recruiting University Hospital, Angers · Angers, Maine et Loire and 2 other locations · NCT06361641

• Curcumin for treating inflammation and symptoms in blood disorders

  This study is testing if a curcumin supplement can help reduce inflammation and improve symptoms in people with certain blood disorders.

  Recruiting at 2 sites Phase 2 University of Southern California · Los Angeles, California and 1 other locations · NCT06063486

• Registry of Asian patients with myeloproliferative neoplasms

  This study is collecting information from Asian patients with myeloproliferative neoplasms to learn more about their condition and how different treatments work for them.

  Recruiting The University of Hong Kong · Hong Kong · NCT05882773

• Comparing Apixaban and Rivaroxaban to Aspirin for Preventing Blood Clots in Certain Blood Disorders

  This study is testing whether the blood thinners Apixaban and Rivaroxaban can prevent blood clots better than low-dose aspirin in patients with certain blood disorders who are at high risk.

  Recruiting at 20 sites Phase 3 University Hospital, Brest · Angers and 41 other locations · NCT05198960

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.